A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical trial NCT04240002 · TERMINATED

Trial details

NCT number: NCT04240002
Sponsor: Astellas Pharma Global Development, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)

Start date: 2020-09-04
Primary completion: 2025-03-11
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.